Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.

Yannick Allanore,Madelon C Vonk,Oliver Distler,Arata Azuma,Maureen D Mayes,Martina Gahlemann,Alexandra James,Veronika Kohlbrenner,Margarida Alves,Dinesh Khanna,Kristin B Highland

Annals of the rheumatic diseases（2022）

引用 8|浏览9

暂无评分

摘要

The safety profile of nintedanib over 52 weeks of SENSCIS-ON was consistent with that reported in SENSCIS. The change in FVC over 52 weeks of SENSCIS-ON was similar to that observed in the nintedanib group of SENSCIS.

查看译文

关键词

Autoimmune Diseases,Pulmonary Fibrosis,Scleroderma, Systemic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要